Influenza A Virus Entry Inhibitors Targeting the Hemagglutinin

Viruses

Jie Yang²  Minmin Li¹  Xintian Shen² 

[1] Department of Clinical Laboratory, The First Affiliated Hospital of Jinan University, Guangzhou 510630, China; E-Mail:;School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; E-Mails:

关键词: influenza A virus;    hemagglutinin;    viral entry;    antiviral drugs;   

DOI  :  10.3390/v5010352

来源: mdpi

【 摘 要 】

Influenza A virus (IAV) has caused seasonal influenza epidemics and influenza pandemics, which resulted in serious threat to public health and socioeconomic impacts. Until now, only 5 drugs belong to two categories are used for prophylaxis and treatment of IAV infection. Hemagglutinin (HA), the envelope glycoprotein of IAV, plays a critical role in viral binding, fusion and entry. Therefore, HA is an attractive target for developing anti‑IAV drugs to block the entry step of IAV infection. Here we reviewed the recent progress in the study of conformational changes of HA during viral fusion process and the development of HA-based IAV entry inhibitors, which may provide a new choice for controlling future influenza pandemics.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.